A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report

par Simona De Summa, Katia Danza, Brunella Pilato, Giuseppina Matera, Rossella Fasano, Angela Calabrese, Rosanna Lacalamita, Nicola Silvestris, Stefania Tommasi, Antonella Argentiero, Oronzo Brunetti
Publié 2021

Regorafenib in metastatic colorectal cancer: more data for clinical decisions

par Vladislav V. Petkau, Alisa A. Karimova, Zinaida V. Akishina
Publié 2021

Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib

par Flavia Fondevila, Carolina Méndez-Blanco, Paula Fernández-Palanca, Tania Payo-Serafín, Jos van Pelt, Chris Verslype, Javier González-Gallego, José L. Mauriz
Publié 2021

Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic

par Marina I. Sekacheva, Anastasia S. Fatyanova, Daur A. Meretukov, Angelina V Zhilenkova, Aleksandr S. Rusanov, Aleksandr A. Rozhkov, Anastasiia A. Guryanova, Nikolay N. Bagmet
Publié 2021

Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib

par M. I. Sekacheva, R. I. Nuriev, A. A. Rozhkov, A. V. Semenkov, N. N. Bagmet, A. M. Boroda
Publié 2020

Preliminary Efficacy and Safety of Camrelizumab in Combination With XELOX Plus Bevacizumab or Regorafenib in Patients With Metastatic Colorectal Cancer: A Retrospective Study

par Hong Zhou, Yuehui Wang, Yanfang Lin, Wenjie Cai, Xiaofeng Li, Xiaomeng He
Publié 2021